Trulieve is poised to make cannabis industry history.
The Florida-based multi-state operator announced that its subordinate voting shares have been approved for listing on the New York Stock Exchange (NYSE), making it the first U.S. cannabis company expected to trade on a major American stock exchange. Trading is scheduled to begin on June 10, 2026, under the ticker symbol TRLV.
The milestone represents a watershed moment for the legal cannabis industry, which has spent years navigating restrictions that largely prevented U.S. plant-touching operators from accessing major domestic exchanges. Until now, most publicly traded cannabis companies with U.S. operations have been limited to Canadian exchanges or over-the-counter markets.
For Trulieve Founder and CEO Kim Rivers, the listing reflects both the company's evolution and broader changes in federal policy.
"As the first U.S. cannabis company to list on a major U.S. exchange, we are excited for the opportunity to expand our shareholder base, increase liquidity, and raise awareness for the benefits of medical marijuana," Rivers said in a statement. "Common sense action by President Trump to reclassify medical marijuana to Schedule III paved the way for this historic milestone."
The announcement follows a series of federal developments that reshaped the regulatory landscape for medical cannabis businesses. In April 2026, Acting Attorney General Todd Blanche formally reclassified medical marijuana to Schedule III following an Executive Order issued by President Donald Trump in December 2025.
According to Trulieve, the final federal order established a pathway for state-licensed medical marijuana operators to obtain Drug Enforcement Administration registration under treaty authority associated with the United Nations Single Convention on Narcotic Drugs.
In response to the regulatory shift, Trulieve completed a corporate restructuring that resulted in the deconsolidation of operations serving both medical and adult-use markets. The company's remaining consolidated business now consists exclusively of state-licensed medical marijuana facilities.
Today, Trulieve's medical footprint includes 206 dispensaries supported by approximately 3.5 million square feet of production capacity registered with the DEA. The company maintains established operations in Florida, Georgia, Pennsylvania, and West Virginia and has identified future growth opportunities in both Georgia and Texas.
"Since inception, Trulieve has focused on serving medical patients with compassion, care, and high-quality products," Rivers said. "With robust cash generation and meaningful catalysts ahead including expansion in Georgia and Texas, Trulieve is well positioned to deliver on our promise to increase access to medical cannabis for U.S. patients."
The company's shares are expected to continue trading on the Canadian Securities Exchange under the symbol TRUL and on the OTCQX under TCNNF until the close of trading on June 9, 2026. Existing shareholders are not required to take any action ahead of the NYSE listing.
Beyond its implications for Trulieve, the uplisting is being viewed as a major signal of the industry's increasing integration into mainstream financial markets. Access to a major U.S. exchange could improve liquidity, attract institutional investors, and provide greater visibility among traditional market participants.
For an industry that has long operated on the margins of federal policy and capital markets, Trulieve's arrival on the NYSE may ultimately be remembered as one of the defining milestones of cannabis' transition into a regulated and increasingly accepted sector of the American economy.
